The Health Is Happiness

Hemophilia treatment

Abner — Thu, 10 Apr 2008 15:41:01 +0000

The hemophilia takes one kind of hereditary disease, so far, does not have the permanent control means. But through increases patient’s hemoglutination factor active level, may eliminate patient’s symptom effectively. May through give the patient the infusion normal person’s blood plasma, increases the patient hemoglutination factor the active level, but a more effective method is, for the patient infusion concentration hemoglutination factor, this is called the hemoglutination factor therapy. However, cannot become effective the too long time by the infusion to patient blood vessel in hemoglutination factor, because each kind of hemoglutination factor has its half-life,?The factor half-life is from 8 to 12 hours,?The factor half-life is from 18 to 24 hours, thus the input blood plasma or the concentration hemoglutination factor’s therapy, can only eliminate the patient symptom temporarily.
    If use for patient regular infusion concentration hemoglutination factor prevention therapy, even if is the specific weight hemophiliac, may also on nearly with the normal person same life, but because the concentration hemoglutination factor is very expensive, China’s patients are very difficult to withstand this prevention therapy, can only after having the hemorrhage the infusion concentration hemoglutination factor.
    Because the concentration hemoglutination factor must withdraw from the massive blood plasmas, thus the hemoglutination factor therapy is very easy to disseminate the virus, in the history once had the massive hemophiliac to infect AIDS, hepatitis B, hepatitis C’s tragedy. in 1985 started to concentrate the hemoglutination factor to carry on heating processing, in 1987 has used the enhancement viral deactivation method, thus caused the concentration hemoglutination factor no longer to disseminate the virus. However, in China, in 1995 only then has not been forbidden after the viral fire fighting processing concentration hemoglutination factor to produce.
    In recent years, countries and so on Canada started with the genetic engineering to produce more inexpensive and the safe concentration hemoglutination factor.

Random Posts

The treatment hemophilia had the new breakthrough

Abner — Thu, 10 Apr 2008 15:40:24 +0000

The sleeve size implants the thing to be able to cause the guinea pig and the monkey produces the treatment hemophilia one kind of protein. The animals will not present the hemorrhage barrier, therefore whether the research to hasn’t implanted the thing to reverse the hemophilia directly to carry on the test. But the blood sample analysis demonstrated that implants the thing to cause on one kind of animal body’s natural protein to transform the certain amount the useful active shape, is called as Factor VIIa, it has used at present in the treatment hemophilia. Researchers for Maryland Dr. Uniformed Services university medical school’s Harvey Pollard and his colleague. The hemophilia is because lacks one kind to press the blood to congeal the protein (i.e. Factor VIII) to create. Doctor may input this kind of protein to the patient to carry on the treatment. But has 15% patients to produce the immune body, prevents to input in vivo protein activeness. These patients may change input Factor VIIa, but this medicine price is expensive, moreover the protein will decompose rapidly. Implants the thing to be possible to avoid the above two kind of situations, and will not cause the body to produce the immune body. Implants the thing is one kind includes can VII transform Factor the Factor VII material the porous room. The researchers put in three in monkey’s abdomen to implant the thing, the result are implanting the thing to take out carry on observe the preceding month, monkey in vivo have produced Factor VIIa. The scientist hoped that in one to two year carries on the human body experiment.

US governs the B hemophilia with the gene therapy

Abner — Thu, 10 Apr 2008 15:39:27 +0000

The US researchers treat the B hemophilia with the gene therapy to obtain the first fruits. American Philadelphia Pediatric hospital’s Katherine · High Dr. and Dr. Standford University medical school Mark · triumphant “Natural Gene Study” on reported in March number that they have carried on the gene therapy security experiment to 3 B hemophiliac, two person of condition obvious changes for the better. Doctor harmless virus which raises specially to the patient intramuscular injection one kind, this kind of virus carries can synthesize the hemoglutination factor IX normal gene. Finally, two patients need to inject the hemoglutination factor IX quantity obvious reduction, the reason are artificially the healthy gene have the function in patient in vivo, makes the hemoglutination factor IX.

Because in vivo lacks the hemoglutination factor, the hemophiliac easy internal hemorrhage and bleeds continues, if to their regular injection hemoglutination factor, the patient does not have life-threatening. B hemophiliac in vivo synthesis hemoglutination factor IX gene existence flaw.

Hemophilia convention method of treatment

Abner — Thu, 10 Apr 2008 15:38:39 +0000

First, partial hematischesis therapy: Fibrin froth, gelatin sponge, zymoplasm, adrenalin and so on.
    Second, substitution therapy
    1st, loses the blood plasma: For the light case’s first choice therapy, inputs the 1000ml fresh blood plasma to be possible to cause the factor?The content enhances normally to 20-25%, an injection dosage is not suitable surpasses the 10-15ml/kg body weight.
    2nd, cold settling: Freezes in the cold precipitation preparation each bag to contain the factor?Activeness is 100u equally, may cause the factor?The blood plasma changes thickly enhances normally to 50% above.
    3rd, factor?, IX concentrating agent: For freezing and drying product, each unit’s factor?, IX activeness is equal in the 1ml normal person fresh blood plasma the average activeness, each kilogram body weight pours into 1u the factor?, may cause in vivo factor?Activeness elevates approximately 2%, but pours into the 1u factor IX only to enhance active 0.5-1%, must every 12 hours supplement one time, the early small hemorrhage uses 10u/kg generally namely effectively, factor?Or the factor IX concentrating agent substitution therapy’s dosage and the usage, the early mild hemorrhage, must supplement that 10u/kg body weight (only 1 time namely enough), the moderate hemorrhage, must supplement that the 20-25u/kg body weight (every 12 hour duplicate injection), the serious hemorrhage, must supplement the 40-50u/kg body weight (later every 12-24 hours will stop or the wound cicatrization for 20u-25u/kg until the hemorrhage. (this is safest at present, conveniently, effective method of treatment)
    Third, other pharmacotherapy:
    1st, suppresses the fibrinolysis medicine. 2nd, reaches that zuo. 3rd, the adrenal cortex hormone has certain curative effect.

The interferon may use in treating the hemophilia baby’s chronic hepatitis C

Abner — Thu, 10 Apr 2008 15:37:56 +0000

Reports and so on South Korean Ko, the application Alpha interferon (IFN-?) treats the hemophilia baby’s chronic hepatitis C is safe effective, has the possibility to obtain the lasting curative effect. Ko et al. take 17 example infection hepatitis C’s hemophilia baby as the objects of study, hemophilia A 15 examples, hemophilia B 2 examples. Conforms to the following standard: Before the treatment, the anti-hepatitis C virus (HCV) immune body masculine gender, in the blood serum has HCV the RNA, ALT level to be bigger than the normal upper limit 1.5 times and continues above 6 months, blood serum hepatitis B virus, human immunodeficiency virus, anti-nuclear immune body and anti-liver - kidney microsome immune body even negative, liver biopsy for chronic hepatitis performance. Gives the following treatment: Hypodermic injection reorganization IFN-? 2a, the dosage is (3.7±0.8) MU/m2/time, 3/weeks, continue for 6 months. Determination blood serum ALT and HCV RNA level. After the treatment had ended, monitors blood serum HCV RNA level 1/in February, continues for 18 months, afterward 1/year. The average revisit time is (3.6±0.6) year. Divides into 3 kinds according to the baby to the IFN response: After continuing the effectiveness (treatment to finish, after 3 year blood serum HCV RNA continued negative), invalid (treatment neutral treatment, after blood serum HCV the RNA even masculine gender) and the recrudescence (treatment had ended, blood serum HCV RNA was negative but in hereafter 3 year internal circulation for masculine gender). (J Pediatr Gastroenterol Nutr 2001,32 ?41) The result showed that in 17 example babies hepatitis C virus genotype 1a 3 examples, 1b 5 examples, 2a 6 examples, 3a 1 example, and some 2 examples for mixed infection (1a +2a). When treatment conclusion in 17 example babies 11 example (65%) ALT level restores normally, simultaneously 9 example (53%) blood serum HCV RNA transfers the negative and the treatment finished 6 months later maintained the negative. In 3 year revisit, 2 example recrudescences, 7 examples (41%) continues effectively, this 7 example baby’s blood serum ALT water average in the treatment starts in the latter 8 weeks to restore normally. To the curative effect different 3 kind of baby’s clinical characteristic, the biochemistry characteristic, the histology characteristic and the virology characteristic perform quite to discover that before continuing the effective group babies to treat, blood serum HCV the RNA level to be lower than the invalid group and the recrudescence group, other aspect not remarkable difference. in 8 example virus gene 1 baby 1 example (13%) to continue effectively, in 6 example virus gene 2 babies 5 examples (83%) to continue effectively.

Blood medicine

Abner — Thu, 10 Apr 2008 15:36:56 +0000

6- amino-caproic acids]Through suppresses the filament to dissolve the system to have an effect. Mainly uses in the fibrinolysin activeness elevating the result the hemorrhage, like gynecology and obstetrics department hemorrhage, internal organs surgery’s and so on after the prostate gland, liver, pancreas, lung hemorrhages. Before the technique the early medication or the technique applies drugs, may reduce in the surgery the oozing of blood, and reduces the amount of blood transfusion.
    [stops bleeding fragrant acid]Function mechanism with ammonia caproic acid, and compared to it. Is suitable in surgery’s the time and so on lung, liver, pancreas, prostate gland, thyroid gland, adrenal gland unusual hemorrhages, in the gynecology and obstetrics department and the postpartum hemorrhage and pulmonary tuberculosis hemoptysis, the phlegm the belt blood, hematuria, the prostate gland large hemorrhage, the upper gastrointestinal hemorrhage and so on. Is remarkable to the chronic oozing of blood effect.
    [sets up hematischesis]This has the kind of zymoplasm type function and the kind of hemoglutination activating enzyme type function, may promote the hemoglutination process.
    [stops bleeding sensitively] This is plays the role through the promotion hemoglutination process. He can increase in the blood blood platelet quantity, strengthens its accumulation and the coherence, the promotion hemoglutination material release, accelerates the hemoglutination. On clinical uses in preventing and the treatment surgical operation bleeds excessively many, the blood platelet reduction purpura or the allergic purpura as well as other reasons cause hemorrhage. This may come in handy with other type haemostatics.
    [An Luoxue]This can promote the blood capillary contraction, reduces the blood capillary permeability, promotes the break blood capillary to break the end the retraction, but plays the hematischesis role.
    [acidum tranexamicum]With stops bleeding the fragrant acid to be similar. Uses in each kind of hemorrhagic disease, when the surgery exceptionally bleeds and so on.
Needs to pay attention: These hematischesis medicine, only then in eight factors (other factors) in the normal situation, only then can be effective.

Hemophilia substitution therapy

Abner — Thu, 10 Apr 2008 15:35:58 +0000

Is at present the most effective treatment method. The position treats as soon as possible, enhances the hemoglutination factor to the hematischesis level, avoids bleeding drafts concurrently, prevents the function to lose. But the present world still had 80% patient not any substitution treatment. The blood plasma product’s production rate only 5%-10%, anxious will be getting more and more deficient along with the blood source and expensive.
    (one) person FVIII concentrate: In the recent 15 years along with viral deactivation technology improvement (dry heat law - HIV? , the organic solvent adds surface active agent method - HCV? , two step viral deactivation law - HAV? ), the blood plasma screening standardization (PCR), the blood products security enhances greatly, blood source dissemination illness gets sick like the hepatitis, AIDS formation rate reduces obviously.
Purity: Including FVIII 1-3U/mg, each 1U/kg may make the blood plasma FVIII level to enhance 2%, including VWF, may also use in the VWD treatment. In vivo period of half change is 8-12 hours. Side effect: Virus infection, anti-FVIII inhibitor production.
    High potency: Including FVIII 50-200U/mg, the use chromatographic analysis technology preparation, does not contain VWF.
    Ultra-high purity: Including FVIII 3000U/mg, the use ionic exchange chromatographic analysis or the monoclonal antibody technology preparation, do not contain VWF,
    Mainly uses in the FVIII inhibitor (high titer, 10-30BU) treatment.
    (two) reorganizes the FVIII concentrate (rFVIII): Expresses through the gene clone technology, in 1990 through the American FDA authorization, its biological activity, the period of half change and blood plasma FVIII was similar, safe, non-viral pollution. But the price is expensive, may also produce the immune body. At present in Canada and Ireland nearly all hemophiliac, American 70% above heavy HA uses the rFVIII treatment. Mainly uses in heavy hemophilia A and the inhibitor treatment.
    First generation of rFVIII (span FVIII): Takes the stabilizer using the human body albumin.
    Second generation of rFVIII (BDD): Replaces the protein using the sucrose to take the stabilizer, FVIII the non-B area, but still retained its activeness, biochemistry characteristic basically with blood plasma product. Because does not contain other human protein, non-immunity activeness, is safer, effective. When uses BDD, an issue of law FVIII:C determination is lower than normal 50%, recommends two issue of law or sends the color substrate law to be possible to result in the ideal result.
    Third generation rFVIII: Using the mouse list anti-, does not contain the human and the animal protein, still place clinical trial stage. In the future will be within a certain number of years, the transgene method production’s person blood plasma product’s output will enhance large scale, will meet the world hemophiliac’s needs hopefully.
    (three) pig FVIII concentrate: Most inhibitors to pig F?The endophilicity compares to person F?The endophilicity is bad, not Yi Yuren F?The immune body has the cross reaction, uses in the high response inhibitor, and bleeds patient’s treatment seriously. Secondary action: Gives off heat mildly, the skin rash, the blood platelet reduces (5%-10%), many and dosage related, occasionally some allergy, not after viral deactivation. Pig and person F?Has the overlapping immunity, approximately 30% produce anti-pig F?The immune body, creates bears the medicine. The emphasis starts the sufficiency, reduces the immune body rapidly, antibody titer <5BU:50u/kg; 5-30BU:75-100u/kg; >30U:100-150u/kg. Recently reorganized pig FVIII entered a phase of clinical trial: Reorganizes person - pig F?The mixture sequence substitutes person FVIII A2 using antigenicity weak non-B the area pig FVIII, activation peptide - A3 and the C2 sequence, reduces the immunogenic and the antigenicity, hopes into the treatment inhibitor the new preparation.
    (four) the FVIII bypass preparation - does not rely on FVIII/FIX the hematischesis preparation
Its mechanism goes round the endocardial hemoglutination way, needs the hemoglutination factor through in the supplement extraneous source or the common hemoglutination way to be possible to achieve the hemoglutination end point similarly.
    (1) zymoplasm original compound (PCC): Including FII, FIX, FX and FVII, mainly use in hemophilia B the treatment. PCC (does not have heparin) also to take “the bypass preparation” widely to use in the treatment which produces the FVIII inhibitor patient to bleed, 75-125U/kg/time, effectiveness 50-60%. May cause the thrombus, after long-term brake like technique, the patient does not advocate uses. in 1974 the international thrombus and the hematischesis committee suggested that in each ml PCC joins the 5-10U heparin to prevent the thrombus.
    (2) activates zymoplasm original compound (APCC): Including ration “F?Inhibitor bypass activeness “(Factor eight inhibitor bypassing activity, FEIBA) PCC (also said that anti-inhibitor hemoglutination compound), had two product Autoplex” (Batex hyland) 50U/kg and FEIBA(Immuno),50-75U/kg, q8-12h. Uses in having the inhibitor hemophilia A hemorrhage treatment, effectiveness reaches 40%-60%. Side effect: The thrombus formation rate is 1%-2%, uses massively repeatedly, the liver complaint, the anti-zymoplasm lacks when easy to occur, if uses 3-4 from now on invalid, then should not use again.

Cold compress therapy operating guide

Abner — Thu, 10 Apr 2008 15:35:14 +0000

Translation: Huang Zikai
??Translates the note: A while ago some blood friends had published some feeling and the opinion at the forum on the cold compress advantages, presently translates section of threads, has the strong feasibility. “Shui Kezai the boat may also the capsized boat”, the use cold compress law also be the same truth, the key is the moderation which uses. Although the cold compress law in the treatment is only the aiding method, but uses also to be possible well to have the twice the result with half the effort effect.
??What advantage does the cold compress therapy have?
??The cold compress may…
????Reduced ache
????Reduced inflammation
????Reduces swelling
????Slows down the hemorrhage
????Reduction muscle spasm
??How should I use the cold compress?
??Regarding is injured the spot use cold compress to have many methods. Below is some suggested:
??Ice bag law:
??Wraps (pea which or corn kernel with the towel the ice sludge either a bag freezes). Wrap the spot which the towel and the among them ice is injured (big ice piece to wrap joint docile not easily) reliably. Cold compress 10 - 15 minutes.
??The low temperature bag (congeals plastic bag, chemistry low temperature bag):
????Wraps up the low temperature bag with the moist thin towel and maintains its flexibility, then according to receives it treats the spot the shape to model the shape. Must model in no way the low temperature the plastic bag directly according to the skin. With low temperature bag cold compress 10 - 15 minutes.
??Ices the cup/ice massage:
Or makes the popsicle in the small paper glass the mold Chinese dress to sail upstream, puts in the refrigerator to freeze prepares the emergency requirement. The time will ice the cup/popsicle mold to be injured the spot to rub directly, does gently reciprocates or the circular motion. Prepares a towel to blot the water which on hand the melt flows off. Massages 5 - 7 minutes gently. This ice therapy uses to be cold.
??Ice-bath:
??Puts in the ice piece has in abundantly cold water barrel. Will be injured the body puts in the water 5 - 15 minutes. This method to the ankle area, the foot, the skill and the hand is suitable, but similarly is also the very cold one method.
??When use cold compress therapy what has to need the careful aspect?
??Yes, certainly has.
??Or scratches the sores use cold compress therapy in the open wound
??Not good or the feeling is not good very badly because of the blood circulation is injured the spot use cold compress therapy
??Confirmed that myself can endure the cold compress therapy. Some children possibly thought that the cold compress therapy is more uncomfortable than the hemorrhage feeling
??The cold compress therapy’s time do not certainly can surpass the recommendation the time. The cold compress time will be excessively long (surpasses 15 minutes) to cause the muscle to be weak, and possibly will also cause blood stream increase!

The interferon may use in treating the hemophilia baby’s chronic hepatitis C

Abner — Thu, 10 Apr 2008 15:33:12 +0000

Reports and so on South Korean Ko, the application Alpha interferon (IFN-?) treats the hemophilia baby’s chronic hepatitis C is safe effective, has the possibility to obtain the lasting curative effect. Ko et al. take 17 example infection hepatitis C’s hemophilia baby as the objects of study, hemophilia A 15 examples, hemophilia B 2 examples. Conforms to the following standard: Before the treatment, the anti-hepatitis C virus (HCV) the immune body masculine gender, in the blood serum has HCV the RNA, ALT level to be bigger than the normal upper limit 1.5 times and continues above 6 months, blood serum hepatitis B virus, human immunodeficiency virus, anti-nuclear immune body and anti-liver - kidney microsome immune body even negative, liver biopsy for chronic hepatitis performance. Gives the following treatment: Hypodermic injection reorganization IFN-? 2a, the dosage for (3.7±0.8) MU/m2/time, 3/weeks, continues for 6 months. Determination blood serum ALT and HCV RNA level. After the treatment had ended, monitors blood serum HCV RNA level 1/in February, continues for 18 months, afterward 1/year. The average revisit time is (3.6±0.6) year. Divides into 3 kinds according to the baby to the IFN response: After continuing the effectiveness (treatment to finish, after 3 year blood serum HCV RNA continued negative), invalid (treatment neutral treatment, after blood serum HCV the RNA even masculine gender) and the recrudescence (treatment had ended, blood serum HCV RNA was negative but in hereafter 3 year internal circulation for masculine gender). (J Pediatr Gastroenterol Nutr 2001,32 ?41)
??The result showed that in 17 example babies hepatitis C virus genotype 1a 3 examples, 1b 5 examples, 2a 6 examples, 3a 1 example, and some 2 examples for mixed infection (1a +2a). When treatment conclusion in 17 example babies 11 examples (65%) the ALT level restores normally, simultaneously 9 examples (53%) blood serum HCV RNA transfers the negative and the treatment finished 6 months later maintained the negative. In 3 year revisit, 2 example recrudescences, 7 examples (41%) continues effectively, this 7 example baby’s blood serum ALT water average in the treatment starts in the latter 8 weeks to restore normally. To the curative effect different 3 kind of baby’s clinical characteristic, the biochemistry characteristic, the histology characteristic and the virology characteristic perform quite to discover that before continuing the effective group babies to treat, blood serum HCV the RNA level to be lower than the invalid group and the recrudescence group, other aspect not remarkable difference. in 8 example virus gene 1 baby 1 example (13%) to continue effectively, in 6 example virus gene 2 babies 5 examples (83%) to continue (P< effectively 0.05). The baby to IFN-? endures good, but has in the treatment initial period gives off heat, myodynia, ill, flu type symptoms and so on headache, has not interrupted the treatment. The minority baby has the abdominal pain (4 examples) and loses hair (2 examples). IFN has not caused the hemorrhage number of times and the hemoglutination factor amount used increases. Only some 1 example baby in IFN treatment period examines to 1 time?The factor inhibiting factor, after the treatment had ended, vanishes.

Random Posts

The phlegm reduction relieves congestion the law

Abner — Thu, 10 Apr 2008 15:31:52 +0000

Human body body fluids being out of balance condenses becomes the edema diseases. Generally will be thick calling “the phlegm”, clear thin calling “drinks”, gathers calls “the edema diseases”. It is because hot, cold, the gas, the fire and so on invade the human body evilly, causes the spleen, the lung, kidney three dirty function being out of balance, affected the body fluids to spread the cloth and the movement normally, caused it to gather lives changes into the edema diseases wet, will affect lives the blood, reduced the hematopoietic function, then affected other internal organs’ function, the serious influence human body’s health. The edema diseases may cause the palpitation, dizzy, the dementia, disgusting vomitive, the gastrectasis few food, the double rib local ruffian full, the few food to accept the difference, asthma cough, the chest to pant, the surface to float the extremity stuffily to swell, the joint ache and so on. The edema diseases may live luo li, the phlegm nucleus, the initially painless but later badly swollen tumor in the physique channels and collaterals, may hinder the gasification, the fresh blood function seriously in the internal organs, may also cause the malignant nosohemia, the myeloma, the lymphocyte leukemia, Hejiejin Jin to get sick, the tumor, the tuberculosis, dropsy, abdominal dropsy and so on.
The Chinese medicine had “all the various illnesses to cause trouble much saying by the phlegm”. The edema diseases stole sanguification important material gas, the body fluids, the water valley subtle and so on, the phlegm gathered for a long time bundle, the hardening became malignant, embezzles the blood, caused in blood’s lymphatic system to have the proliferation and to become malignant, has seized in blood’s normal cell differentiation and the growth quarter.
In the nosohemia dialectical executes, the phlegm reduction must be good for the spleen, the clear lung, to invigorate the kidney, makes this three dirty to restore and to enhance the hematopoietic function. Because it is evilly “wet”, is “solid”, therefore should take “dry or wet” and “relieves congestion” as the treatment principle. Nosohemia which causes because of the edema diseases, must take lymphatic system’s change, pays attention to disease’s trend, sickness is “wet solid”, therefore, when by “warm dry”, but melts it, do not neglect nosohemia’s characteristic.

The Health Is Happiness

Hemophilia treatment

Random Posts

The treatment hemophilia had the new breakthrough

Related Posts

US governs the B hemophilia with the gene therapy

Related Posts

Hemophilia convention method of treatment

Related Posts

The interferon may use in treating the hemophilia baby’s chronic hepatitis C

Related Posts

Blood medicine

Related Posts

Hemophilia substitution therapy

Related Posts

Cold compress therapy operating guide

Related Posts

The interferon may use in treating the hemophilia baby’s chronic hepatitis C

Random Posts

The phlegm reduction relieves congestion the law

Related Posts